Home / Peptides / Peptides for Weight Loss

Peptides for Weight Loss: How Much GLP-1 Drugs and GH Secretagogues Really Deliver

GLP-1 peptides do the heavy lifting: semaglutide averaged 14.9% and tirzepatide up to 20.9% body-weight loss in pivotal trials. GH-secretagogue peptides shift fat distribution and protect lean mass but do not drive large weight loss on their own.

M
Written by
B.Sc. (Hons) Chemistry, MBA Pharma Mgmt (Pursuing) · Scientific Content Writer, Strong Health
D
Medically reviewed by
M.D., Board-Certified Psychiatrist · Medical Reviewer, Strong Health
Published: July 16, 2026 Updated: November 3, 2026 · Editorial Standards
10 min read

Key takeaways

  • The peptides that produce large weight loss are the GLP-1 drugs: semaglutide 2.4 mg averaged −14.9% body weight over 68 weeks (vs −2.4% placebo) and tirzepatide 15 mg averaged −20.9% over 72 weeks (vs −3.1%).[1][2]
  • GH-secretagogue peptides (tesamorelin, ipamorelin, CJC-1295) shift fat distribution and support lean mass but do not drive double-digit weight loss on their own.[4][6]
  • Semaglutide also reduced major cardiovascular events in adults with obesity and no diabetes in the SELECT trial.[7]
  • Rapid weight loss costs muscle: pair GLP-1 therapy with resistance training, 1.0–1.5 g/kg/day of protein, and DEXA tracking to separate fat loss from lean-mass loss.
  • Gastrointestinal side effects are the most common and are concentrated during dose escalation; 4–7% of tirzepatide participants stopped for adverse events versus 2.6% on placebo.[2]

Which peptides are used for weight loss?

Two categories of peptide are used for medical weight loss: GLP-1 receptor agonists and GH-secretagogue peptides. GLP-1 drugs (semaglutide, tirzepatide) reduce appetite and produced 15–21% average weight loss in their pivotal trials,[1][2] while GH secretagogues (tesamorelin, ipamorelin, CJC-1295) shift fat distribution and help protect lean mass but do not drive large weight loss on their own. This guide covers overall weight loss; for the narrower question of visceral (belly) fat specifically, see our dedicated guide to peptides for visceral belly fat.

How much weight do semaglutide and tirzepatide produce?

Semaglutide 2.4 mg produced a mean 14.9% body-weight loss over 68 weeks versus 2.4% on placebo in the STEP 1 trial, and tirzepatide produced 15.0% to 20.9% over 72 weeks versus 3.1% on placebo in SURMOUNT-1. Semaglutide and tirzepatide are peptide-based medications that mimic gut hormones to reduce appetite. In the STEP 1 trial, once-weekly semaglutide produced substantial, sustained weight loss versus placebo,[1] and tirzepatide showed even larger reductions in the SURMOUNT-1 trial.[2] The headline numbers:

Placebo-controlled weight loss in the pivotal GLP-1 trials
Trial Drug and dose Duration Mean weight change Placebo
STEP 1 (n=1,961)[1] Semaglutide 2.4 mg weekly 68 weeks −14.9% −2.4%
SURMOUNT-1 (n=2,539)[2] Tirzepatide 5 mg weekly 72 weeks −15.0% −3.1%
SURMOUNT-1[2] Tirzepatide 10 mg weekly 72 weeks −19.5% −3.1%
SURMOUNT-1[2] Tirzepatide 15 mg weekly 72 weeks −20.9% −3.1%

“The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points.”

Wilding JPH, et al., STEP 1 trial, New England Journal of Medicine, 2021 — PubMed

Both work through GLP-1 signaling pathways that regulate appetite and satiety.[3]

Nutrition still does much of the work. Our semaglutide diet guide covers how to structure eating for the best results on these medications.

Do GH secretagogue peptides burn fat?

GH secretagogues reduce visceral (deep abdominal) fat rather than total body weight. Tesamorelin lowered visceral adipose tissue in controlled HIV trials,[4] and growth hormone reduced abdominal fat mass in abdominally obese men,[5] but neither produces the double-digit weight loss seen with GLP-1 drugs. These peptides are often considered when the goal is fat distribution and body composition rather than total scale weight alone.

How do you protect muscle while losing weight on peptides?

Protecting muscle during GLP-1 weight loss comes down to resistance training, 1.0–1.5 g/kg/day of protein, and tracking body composition with DEXA rather than the scale. Rapid weight loss can cost muscle as well as fat. Oral GH-secretagogue therapy has been shown to improve body composition in older adults by supporting lean mass,[6] which is one reason peptides are sometimes paired with GLP-1 programs. Progress is best tracked with a DEXA body-composition scan that separates fat loss from lean-mass loss, and patients focused on building muscle can review our guide to peptides for muscle growth.

How is a physician-supervised weight-loss protocol designed?

Strong Health weight-loss protocols start with a physician evaluation, metabolic labs, and a body-composition baseline. Medication choice, dose titration, and any peptide pairing are individualized and monitored on a schedule. Beyond weight, GLP-1 therapy has been associated with cardiovascular benefit in people with obesity and without diabetes.[7] Locally, our medical weight-loss clinic in Miami designs and supervises these programs.

What are the side effects of weight-loss peptides?

The most common side effects of GLP-1 medications are gastrointestinal (nausea, vomiting, diarrhea, constipation), mostly mild to moderate and concentrated during dose escalation; in SURMOUNT-1 they led 4–7% of tirzepatide participants to stop treatment versus 2.6% on placebo[2]. GH-secretagogue peptides are generally well tolerated under supervision, with contraindications including active malignancy and certain endocrine disorders. Every protocol requires physician oversight and ongoing monitoring. Explore all options in our peptide therapy hub.

Frequently Asked Questions

Which peptides help with weight loss?
Two categories are used clinically. GLP-1 receptor agonists (semaglutide and tirzepatide) are peptide-based medications that reduce appetite and food intake. GH-secretagogue peptides such as Tesamorelin influence fat metabolism and body composition. The right choice depends on your goals, labs, and physician evaluation.
Are GLP-1 medications like semaglutide actually peptides?
Yes. Semaglutide, liraglutide and tirzepatide are synthetic peptides: chains of amino acids modeled on the gut hormone GLP-1 (tirzepatide also mimics GIP). They are FDA-approved prescription drugs with full phase 3 trials, which separates them from research-chemical peptides sold online. In practice, when a clinic says "peptide weight loss," the medication doing the heavy lifting is almost always one of these GLP-1 drugs rather than a growth hormone secretagogue.
Will I lose muscle on a peptide weight-loss protocol?
Any rapid weight loss can cost lean mass along with fat, which is why body composition, not just scale weight, is tracked with a DEXA scan. GH-secretagogue peptides are sometimes paired with GLP-1 programs specifically to support lean mass during a caloric deficit, under physician supervision.
How is this different from the peptides-for-belly-fat page?
This guide covers total weight loss, where GLP-1 medications are the primary tool and the goal is a large, sustained reduction in body weight. The belly-fat guide covers visceral (deep abdominal) fat specifically, where GH secretagogues such as tesamorelin have controlled-trial evidence for reducing visceral adipose tissue without large changes in total weight. Many patients use both approaches in sequence: GLP-1 therapy for weight, then body-composition work for fat distribution.
Do I have to stay on weight-loss peptides forever?
Not necessarily, but weight regain after stopping GLP-1 medication is common because appetite returns to baseline, so the decision is planned rather than abrupt. Options include tapering to a lower maintenance dose, switching to intermittent dosing, or stopping once habits, protein intake and resistance training are established and body composition is stable on DEXA. Your physician sets the plan based on your response, side effects and the reason weight was gained in the first place.
Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Authorship and review information are shown where recorded; an editorial update is not a new medical review.

Related Articles

Molecules in this guide

Browse the molecule library →

Compare the research, safety questions and regulatory context for each molecule. Inclusion in this guide does not establish effectiveness or treatment availability.

Looking for care? View Strong Health locations and visit options.

Want a Physician-Supervised Weight-Loss Plan?

Our physicians evaluate your metabolic profile and design an individualized program built around GLP-1 therapy, peptide pairing, and body-composition tracking, all monitored by the same physician.

References & Citations

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
  3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
  4. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. N Engl J Med. 2007;357(23):2359-2370.
  5. Johannsson G, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass. J Clin Endocrinol Metab. 1997;82(3):727-734.
  6. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611.
  7. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
  8. FDA. Human Drug Compounding. Accessed November 3, 2026.
  9. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026; accessed November 3, 2026.
👉 Book a Free Peptide Therapy Assessment